Pharmacoeconomic analysis of first line meropenem versus standard antibiotic treatment in seriously infected secondary nosocomial sepsis syndrome patients.
Study identifier:3591/9014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Pharmacoeconomic analysis of first line meropenem versus standard antibiotic treatment in seriously infected secondary nosocomial sepsis syndrome patients. An open, randomized multi-center study.
Medical condition
Sepsis
Phase
Phase 4
Healthy volunteers
No
Study drug
Meropenem
Sex
All
Actual Enrollment
160
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jan 2002
Primary Completion Date: 01 Jun 2006
Study Completion Date: 01 Jun 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca CRR Central and Eastern Europe, Hungary Medical Director
AstraZeneca
